Filter by: patients
Home > Community Treatment Reports and Side Effects > Adalimumab Treatment Report
What is Adalimumab?

Adalimumab is used in the treatment of active rheumatoid arthritis and active psoriatic arthritis. Also used for Crohn's disease in patients with inadequate response to conventional treatment.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
RA (Rheumatoid Arthritis) 102 30 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Psoriasis 34 11 Efficacy_major Efficacy_slight Efficacy_none
Crohn's Disease 33 10 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
Ankylosing Spondylitis 19 3 Efficacy_major Efficacy_slight
Psoriatic Arthritis 14 3 Efficacy_major Efficacy_slight
Rheumatoid Arthritis 6 1 Efficacy_cant_tell

See all 177 patients currently taking Adalimumab

Mouse over the table for more information

Reported Dosages

Frequently reported dosages based on patients currently taking Adalimumab. See all 14 dosages ►

  40mg/0.8mL as needed 20 mg/0.4 mL every other week 20 mg/0.4 mL weekly 40 mg/0.8 mL every other week 40 mg/0.8 mL weekly 2 x 40 mg/0.8 mL every other week 2 x 40 mg/0.8 mL weekly 20 mg/0.4 mL daily 40 mg/0.8 mL daily 4 x 40 mg/0.8 mL one time
  3 Number of Patients: 3 9 Number of Patients: 9 2 Number of Patients: 2 142 Number of Patients: 142 19 Number of Patients: 19 2 Number of Patients: 2 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Adalimumab (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 31   Did not seem to work: 48%
Side effects too severe 23   Side effects too severe: 36%
Doctor's advice 16   Doctor's advice: 25%
Other 13   Other: 20%
Expense 4   Expense: 6%
Change in health plan coverage 3   Change in health plan coverage: 5%
Personal research 2   Personal research: 3%
Not indicated 2   Not indicated: 3%

See all 64 patients who’ve stopped taking Adalimumab

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Adalimumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Stopped Taking Adalimumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Adalimumab

Always
 51 86%
Usually
 6 10%
Sometimes
 1 2%
Never
 1 2%

Burden

Difficulty being on treatment

Burden of Adalimumab

Very
 5 8%
Somewhat
 15 25%
A little
 13 22%
Not at all
 26 44%

Cost

Paid out of pocket

Cost of Adalimumab

$200+
 5 12%
$100-199
 0 0%
$50-99
 4 10%
$25-49
 2 5%
< $25
 30 73%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.